See the DrugPatentWatch profile for bosulif

Based on the information available, the manufacturing process for Bosulif, a medication used to treat chronic myelogenous leukemia, is covered by several patents. Bosulif is manufactured by Pfizer and was approved by the FDA in 2012.

A search of DrugPatentWatch.com, a comprehensive database of drug patents, reveals several patents related to Bosulif. The patents cover various aspects of the drug, including its formulation, manufacturing process, and therapeutic uses.

One of the patents covering the manufacturing process for Bosulif is US Patent No. 8,669,193, titled "Process for preparing bosutinib and its salts." The patent describes a method for preparing bosutinib, the active ingredient in Bosulif, and its salts. The method involves reacting a specific intermediate compound with a particular reagent under specific conditions.

Another patent related to the manufacturing process for Bosulif is US Patent No. 8,772,184, titled "Process for preparing bosutinib and its salts." This patent also covers a method for preparing bosutinib and its salts, but it involves a different intermediate compound and reaction conditions than those described in Patent No. 8,669,193.

It's worth noting that these patents cover the manufacturing process for bosutinib, the active ingredient in Bosulif, rather than the final drug product itself. However, the manufacturing process for the active ingredient is a critical aspect of the drug's production, and these patents provide Pfizer with exclusive rights to produce bosutinib using these specific methods.

In summary, the manufacturing process for Bosulif is covered by several patents, including US Patent Nos. 8,669,193 and 8,772,184. These patents cover methods for preparing bosutinib, the active ingredient in Bosulif, and its salts.

Sources:

* [DrugPatentWatch.com](https://www.drugpatentwatch.com/drugs/bosulif)
* US Patent No. 8,669,193
* US Patent No. 8,772,184